Editing Avolition (section)

==Treatment==
Antipsychotics are less effective in the treatment of negative symptoms of schizophrenia such as avolition than for positive symptoms.<ref name=CarsonNursing>{{cite book | last1 = Carson | first1 = Verna Benner | name-list-style = vanc | title = Mental health nursing: the nurse-patient journey | date = 2000 | publisher = W.B. Saunders | location = Philadelphia | isbn = 978-0-7216-8053-8 | page = 638 | edition = 2nd | url = https://books.google.com/books?id=QM5rAAAAMAAJ | access-date = 2016-05-06 | archive-date = 2016-11-25 | archive-url = https://web.archive.org/web/20161125003432/https://books.google.com/books?id=QM5rAAAAMAAJ | url-status = live}}</ref> Low dose [[amisulpride]] has shown to be more effective than placebo for treating the negative symptoms of schizophrenia, which includes avolition. It works by blocking pre-synaptic dopamine receptors, causing a release of dopamine into the synapse.<ref name="pmid29368205">{{cite journal |vauthors=Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, Leucht S |date=October 2018 |title=Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis |url=https://boris.unibe.ch/110770/10/Krause%20EurArchPsychiatryClinNeurosci%202018_postprint.pdf |journal=European Archives of Psychiatry and Clinical Neuroscience |volume=268 |issue=7 |pages=625–639 |doi=10.1007/s00406-018-0869-3 |pmid=29368205 |s2cid=24569827}}</ref>

Compared with [[social skills training]] (SST), [[Cognitive behavioral therapy|cognitive behavioural therapy]] (CBT) shows more promise in treating the negative symptoms of schizophrenia, including avolition.<ref>{{cite journal |vauthors=Elis O, Caponigro JM, Kring AM |date=December 2013 |title=Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions |journal=Clinical Psychology Review |volume=33 |issue=8 |pages=914–28 |doi=10.1016/j.cpr.2013.07.001 |pmc=4092118 |pmid=23988452}}</ref>

According to a 2015 article, [[aripiprazole]] may be useful for treatment of apathy syndrome (avolition). However, its role and efficacy in treatment of apathy requires further investigation in clinical trials.<ref>{{cite journal |title=Aripiprazole for Treatment of Apathy |journal=Innovations in Clinical Neuroscience |volume=12 |issue=9–10 |pages=33–36 |pmc=4655898 |year=2015 |last1=Monga |first1=V. |last2=Padala |first2=P. R. |pmid=26634180}}</ref> A comparison to amisulpride published in 2022, found that aripiprazole was effective in treating negative symptoms, while amisulpride was not.<ref>{{Cite journal |last1=Nielsen |first1=Mette Ødegaard |last2=Kristensen |first2=Tina Dam |last3=Borup Bojesen |first3=Kirsten |last4=Glenthøj |first4=Birte Y. |last5=Lemvigh |first5=Cecilie K. |last6=Ebdrup |first6=Bjørn H. |date=2022-03-17 |title=Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses |journal=Frontiers in Psychiatry |volume=13 |doi=10.3389/fpsyt.2022.834333 |issn=1664-0640 |pmc=8969108 |pmid=35370857 |doi-access=free }}</ref>{{Primary source inline|date=August 2023}}

According to a 2020 study, [[mitragynine]] contained in [[kratom]] may have the ability to reduce avolition.<ref>{{cite journal | title=The Potential for Kratom as an Antidepressant and Antipsychotic | year=2020| pmc=7309668| last1=Johnson| first1=L. E.| last2=Balyan| first2=L.| last3=Magdalany| first3=A.| last4=Saeed| first4=F.| last5=Salinas| first5=R.| last6=Wallace| first6=S.| last7=Veltri| first7=C. A.| last8=Swogger| first8=M. T.| last9=Walsh| first9=Z.| last10=Grundmann| first10=O.| journal=The Yale Journal of Biology and Medicine| volume=93| issue=2| pages=283–289| pmid=32607089}}</ref>